https://www.selleckchem.com/products/tp-0903.html
Specifically, the median duration of overall survival was 36 versus 8 months in NSCLC in those with two or more versus none of the 52 genes mutated. Moreover, those patients with the compound mutation signature but had low TMB (1 achieved significant overall survival benefits when compared with those without the signature but had TMB-H (≥1. Finally, in an independent cohort of 156 patients with ICB-treated NSCLC, the median duration of progression-free survival was 8.3 months versus 3.5 months in those with the compound mutation
Like
Comment
Share
